Literature DB >> 14607309

Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy.

Vittorio Govoni1, Enrico Granieri, Mauro Manconi, Jay Capone, Ilaria Casetta.   

Abstract

There have been many reports of cases of Guillain-Barré syndrome (GBS) after therapeutic injection of bovine ganglioside preparations with the result that they were withdrawn in Italy in December 1993. As the relationship between bovine gangliosides and GBS has not yet been established, a further epidemiological investigation in the Local Health District (LHD) of Ferrara, Italy, was carried out in the years 1994-2001 to verify whether the incidence of GBS had changed after ganglioside withdrawal. The other aim of this investigation was to update the incidence of GBS in this area since the two previous investigations we carried out showed an increase in incidence from the years 1981-1987 to the years 1988-1993. The cases of GBS were identified prospectively. To guarantee completeness of case ascertainment, an intensive retrospective survey of all possible sources of cases for the entire study period was performed. The mean annual crude incidence rate in the years 1994-2001 (based on 26 new cases) was 1.97 per 100,000 population (95% CI 1.29-2.89), whereas it had been 1.87 per 100,000 population (95% CI 1.35-2.52) in the years 1981-1993 (based on 43 cases) when gangliosides were available. The age-adjusted rates were almost identical (1.66 and 1.65 per 100,000 population, respectively). Although ganglioside administration could have triggered, on the basis of an individual susceptibility, an immunologic reaction which produced GBS, the incidence of GBS in the study area did not change after ganglioside withdrawal. In the whole period 1981-2001, a temporal pattern of incidence was reported with an increase towards a peak in 1990-1992 and a progressive decline thereafter. This temporal pattern did not seem related to ganglioside withdrawal, and no definite explanation for it was found which could imply that the disease incidence is less stable than it was deemed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607309     DOI: 10.1016/s0022-510x(03)00215-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  14 in total

Review 1.  Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis.

Authors:  James J Sejvar; Andrew L Baughman; Matthew Wise; Oliver W Morgan
Journal:  Neuroepidemiology       Date:  2011-03-21       Impact factor: 3.282

2.  [Co-existence of Guillain-Barré syndrome and Behcet syndrome: A case report].

Authors:  C Yu; C Li; Y Y Fan; Y Xu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

3.  Temporal trend of amyotrophic lateral sclerosis incidence in southern Europe: a population study in the health district of Ferrara, Italy.

Authors:  Vittorio Govoni; Edward Cesnik; Ilaria Casetta; Valeria Tugnoli; Maria Rosaria Tola; Enrico Granieri
Journal:  J Neurol       Date:  2012-01-10       Impact factor: 4.849

Review 4.  GM1 Ganglioside: Past Studies and Future Potential.

Authors:  Massimo Aureli; Laura Mauri; Maria Grazia Ciampa; Alessandro Prinetti; Gino Toffano; Cynthia Secchieri; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2015-03-12       Impact factor: 5.590

5.  Nitric oxide and potassium channels mediate GM1 ganglioside-induced vasorelaxation.

Authors:  Ana Flávia Furian; Yanna Dantas Rattmann; Mauro Schneider Oliveira; Luiz Fernando Freire Royes; Maria Consuelo Andrade Marques; Adair Roberto Soares Santos; Carlos Fernando Mello
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-06       Impact factor: 3.000

Review 6.  Axonal variants of Guillain-Barré syndrome: an update.

Authors:  Pei Shang; Mingqin Zhu; Ying Wang; Xiangyu Zheng; Xiujuan Wu; Jie Zhu; Jiachun Feng; Hong-Liang Zhang
Journal:  J Neurol       Date:  2020-03-05       Impact factor: 4.849

7.  The urgent neurological consultation in the population of the province of Ferrara, Italy.

Authors:  Vittorio Govoni; Elena Della Coletta; Elisa Fallica; Edward Cesnik
Journal:  Neurol Sci       Date:  2018-05-01       Impact factor: 3.307

8.  A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

Authors:  Jay S Schneider; Stephen M Gollomp; Stephanie Sendek; Amy Colcher; Franca Cambi; Wei Du
Journal:  J Neurol Sci       Date:  2012-11-28       Impact factor: 3.181

9.  Risk Factors for Mechanical Ventilation in Patients with Guillain-Barré Syndrome.

Authors:  Yanwei Cheng; Kangding Liu; Chunrong Li; Weiwei Zhang; Xiujuan Wu; Shaokuan Fang
Journal:  Neurocrit Care       Date:  2022-03-25       Impact factor: 3.532

10.  More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast China.

Authors:  Xiujuan Wu; Wei Wu; Zhengzheng Wang; Donghui Shen; Wei Pan; Ying Wang; Limin Wu; Xiaokun Wu; Jiachun Feng; Kangding Liu; Jie Zhu; Hong-Liang Zhang
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.